|
FDA grants accelerated approval to new treatment for advanced ovarian cancer
|
20 December 2016 |
|
FDA research to help speed development of Zika virus vaccines and therapeutics
|
17 November 2016 |
|
FDA awards 21 grants to stimulate product development for rare diseases
|
17 October 2016 |
|
FDA launches #NaloxoneApp competition to spur innovative technologies to help reduce opioid overdose deaths
|
21 September 2016 |
|
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy
|
19 September 2016 |
|
FDA updates warnings for fluoroquinolone antibiotics
|
26 July 2016 |
|
FDA approves new medication for dry eye disease
|
12 July 2016 |
|
FDA advances Precision Medicine Initiative by issuing draft guidances on next generation sequencing-based tests
|
08 July 2016 |
|
FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX
|
10 June 2016 |
|
FDA approves first buprenorphine implant for treatment of opioid dependence
|
26 May 2016 |
|
FDA approves new treatment for inhalation anthrax
|
22 March 2016 |
|
FDA takes additional action to better understand safety of Essure, inform patients of potential risks
|
01 March 2016 |
|
FDA providing $2 million in new grants for natural history studies in rare diseases
|
29 February 2016 |
|
FDA seeks $5.1 billion total for FY 2017
|
10 February 2016 |
|
Califf, FDA top officials call for sweeping review of agency opioids policies
|
04 February 2016 |
|
FDA approves first drug to show survival benefit in liposarcoma
|
28 January 2016 |
|
FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients
|
08 December 2015 |
|
FDA approves Opdivo to treat advanced form of kidney cancer
|
24 November 2015 |
|
FDA approves new treatment for HIV
|
06 November 2015 |
|
FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa
|
19 October 2015 |